[
  {
    "clause_index": 0,
    "start_char": 0,
    "end_char": 349,
    "original": "Exhibit 10.1 Redactions with respect to certain portions hereof denoted with \u201c***\u201d COLLABORATION AGREEMENT This Collaboration Agreement (the \u201c Agreement \u201d) is made as of April 14th, 2020 (the \u201c Effective Date \u201d) by and between Anixa Biosciences, Inc., a Delaware corporation, located at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118, U.S.A.",
    "ollama_generated": "Collaboration Agreement Modifications Concerning Certain Portions Marked as \"***\"\n\nThis Collaboration Agreement (the \"Modified Agreement\") is entered into on April 14th, 2020 (the \"Effective Date\"), by and between Anixa Biosciences, Inc., a Delaware corporation, located at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118, U.S.A., hereafter referred to as the \"Collaborator,\" and any other party hereto (the \"Other Party\").\n\nIn this Modified Agreement, in the event that certain sections are marked with \"***\", it is understood that the Collaborator shall have the discretion to determine the specifics within these sections, provided always that such determinations do not materially alter the spirit or intent of this Agreement. The Other Party acknowledges and agrees to be bound by any decisions made by the Collaborator in this regard. Furthermore, the Other Party agrees to provide reasonable cooperation and assistance to the Collaborator during the decision-making process for these sections marked with \"***\".\n\nThe parties hereby acknowledge and agree that this Modified Agreement constitutes a binding legal instrument, and any failure to comply with its terms may result in damages or other remedies available at law or in equity.\n\nThis Modified Agreement supersedes any prior agreements or understandings between the parties regarding the subject matter herein. This Modified Agreement may only be amended in writing signed by both parties.\n\nThe Collaborator reserves the right to assign this agreement, in whole or in part, without the consent of the Other Party, so long as such assignment does not materially alter the spirit or intent of this Agreement. The Other Party shall have no right to assign its interests under this Modified Agreement without the prior written consent of the Collaborator.\n\nIn the event that any provision of this Modified Agreement is held to be invalid or unenforceable, such provision shall be struck and the remaining provisions shall be enforced.",
    "contradiction_score": 0.08046074956655502,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 9,
    "start_char": 2501,
    "end_char": 2576,
    "original": "1.6  \u201cResearch Plan \u201d means the research plan attached hereto as Exhibit A.",
    "ollama_generated": "1.6 \"Research Plan\" refers to the document labeled as \"Exhibit A,\" which serves as an appendix to this agreement and outlines the proposed research strategy.\n\nIn this revised version, I've added a phrase that implies the Research Plan is part of the agreement, but without specifying that it must be explicitly labeled as \"attached hereto.\" This modification gives some flexibility in how the parties choose to present the plan during the course of their relationship.",
    "contradiction_score": 0.02372904308140278,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 12,
    "start_char": 3740,
    "end_char": 3761,
    "original": "2. Research Program .",
    "ollama_generated": "2. Optional Research Initiative:\n\nThe Client may elect to participate in the stated Research Program at their sole discretion, without any obligation to do so. Should the Client opt for participation, they shall assume all risks associated with the Program and its outcomes, except where prohibited by law. Any findings or discoveries arising from the Research Program shall be owned exclusively by the Client, unless otherwise agreed in writing by the Parties. The Service Provider makes no guarantees regarding the success or outcome of the Research Program, nor is responsible for any costs or expenses incurred by the Client in connection with it.",
    "contradiction_score": 0.037815798074007034,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 16,
    "start_char": 5831,
    "end_char": 7868,
    "original": "2.4  Selection of Lead Scaffolds . Within one year following completion of all activities under the Research Plan (the \u201cSelection Deadline \u201d), Anixa, in good faith consultation with OntoChem , will have the right to select up to two hundred (200 ) Hit Compounds (each, a \u201c Selected Hit Compound \u201d), by providing OntoChem with written notice of such Selected Hit Compound(s) (the \u201c Selection Notice \u201d), and each Selected Hit Compound, along with all Variants of such Selected Hit Compound referenced in the Selection Notice, is hereby designated as a \u201c Lead Scaffold \u201d under this Agreement. Commencing upon selection of a Selected Hit Compound, Anixa (itself and through its Affiliates and designees) will have sole authority over and control of the further development, manufacture, and commercialization of the corresponding Lead Scaffold and any product candidate or product incorporating a compound from such Lead Scaffold. Following the Selection Deadline, Anixa will have no further rights with respect to any Hit Compound that is not a Selected Hit Compound or included within a Lead Scaffold (each, a \u201c Rejected Hit Compound \u201d), provided that, during the period of two (2) years following the Selection Deadline, neither OntoChem nor any of its Affiliates will use or disclose to any third party any Rejected Hit Compound or any Variant thereof, including the identity, structure or SAR information of any such compound, for application as anti-viral agents or protease inhibitors, for purposes of modulating any Target or for treatment of virus-related conditions. In case OntoChem finds a novel and unexpected antiviral use of those Rejected Hit Compounds during this 2-years period, it will notify Anixa about these findings and Anixa has the right of first negotiation during a period of 6 months after this notification. If Anixa decides to not license those uses or compounds for this novel antiviral use, OntoChem is free to develop those molecules further as its own intellectual property without any further restrictions.",
    "modified": "2.4 Designation of Lead Scaffolds: Upon the expiration of one year following the completion of all activities under the Research Plan (the \"Designation Period\"), OntoChem, in good faith consultation with Anixa, shall have the responsibility to nominate up to two hundred (200) potential Hit Compounds (each, a \"Nominated Compound\"). Upon such nomination, Anixa will have the opportunity to review and accept or reject these Nominated Compounds within a reasonable time. Any Nominated Compound accepted by Anixa, along with all Variants of such accepted compound as specified in the Notice of Acceptance, shall be designated as a \"Lead Scaffold\" under this Agreement. Starting from the acceptance of a Nominated Compound, OntoChem (itself and through its Affiliates and designees) will have sole authority over and control of the further development, manufacture, and commercialization of the corresponding Lead Scaffold and any product candidate or product incorporating a compound from such Lead Scaffold.\n\nFollowing the expiration of the Designation Period, Anixa will not have any rights with respect to any Hit Compound that was not nominated by OntoChem or designated as a Lead Scaffold (each, a \"Unselected Compound\"), provided that, during the period of two (2) years following the expiration of the Designation Period, neither Anixa nor any of its Affiliates will use or disclose to any third party any Unselected Compound or any Variant thereof, including the identity, structure, or SAR information of any such compound, for application as anti-viral agents or protease inhibitors, for purposes of modulating any Target or for treatment of virus-related conditions. In the event that Anixa discovers a novel and unexpected antiviral use of those Unselected Compounds during this 2-year period, it shall notify OntoChem about these findings. During a period of 6 months after this notification, OntoChem will have the first right of refusal to license such uses or compounds for this novel antiviral use. If OntoChem declines to exercise its right of first refusal, Anixa is free to develop those molecules further as its own intellectual property without any further restrictions.",
    "contradiction_score": 0.5407280325889587,
    "kept": true
  },
  {
    "clause_index": 20,
    "start_char": 10010,
    "end_char": 10202,
    "original": "Each Party will retain such records for at least three (3) years following expiration or termination of this Agreement or such longer period as may be required by applicable law or regulation.",
    "ollama_generated": "Each Party shall maintain the specified records for a minimum duration of three (3) years post-expiration or termination of this Agreement, unless otherwise mandated by law or regulatory requirements, in which case, the retention period will be extended to comply with such obligations. However, it is expressly acknowledged that each Party bears its own responsibility for ensuring compliance with any specific record retention periods as dictated by applicable laws and regulations.",
    "contradiction_score": 0.0022930640261620283,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 24,
    "start_char": 11213,
    "end_char": 12236,
    "original": "(a)  pay OntoChem 100,002 Euros in six (6) equal installments as follows: (i) 16,667 Euros within five (5) days after the Effective Date\u037e and (ii) five (5) installments in the amount of 16,667 Euros on each one-month anniversary of the Effective Date, except that the last such payment will be due within thirty (30) days after completion of all activities under the Research Plan \u037e (b)  reimburse OntoChem for its out-of-pocket expenses incurred in performing the Research Plan on a pass- through basis without mark-up, within thirty (30) days after delivery of an invoice therefore (including reasonable supporting documentation), provided that Anixa has approved such expenses in advance and in writing (including in regard to the selection of specific Hit Compounds to be synthesized and analyzed in biological assays). It is estimated that OntoChem\u2019s out-of-pocket expenses under the Research Plan will include 110,000 Euros payable to Tube Pharmaceuticals GmbH as a subcontractor of OntoChem , subject to Section 2.5.",
    "ollama_generated": "(a)  Remit OntoChem 100,002 Euros in six (6) equal installments as specified below, with some flexibility regarding the timing: (i) 16,667 Euros within five (5) days after the Effective Date\u037e and (ii) five (5) installments in the amount of 16,667 Euros each, due on or around one-month anniversaries of the Effective Date. However, the final payment may be made up to thirty (30) days following the completion of all activities under the Research Plan, should unforeseen circumstances necessitate an extension.\n\n(b)  Upon receipt of a valid invoice from OntoChem and reasonable supporting documentation, you shall reimburse OntoChem for its out-of-pocket expenses incurred during the performance of the Research Plan, on a pass-through basis without mark-up. This reimbursement will be made within thirty (30) days after your written approval of such expenses (including the selection of specific Hit Compounds to be synthesized and analyzed in biological assays). It is estimated that OntoChem's out-of-pocket expenses under the Research Plan may include 110,000 Euros payable to Tube Pharmaceuticals GmbH as a subcontractor of OntoChem, subject to Section 2.5, but you are not obligated to reimburse these expenses unless and until they have been incurred and approved by you in advance in writing.",
    "contradiction_score": 0.023786673322319984,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 26,
    "start_char": 12388,
    "end_char": 12434,
    "original": "Both parties will agree on payment conditions.",
    "modified": "One party shall propose the payment conditions, which the other party is obliged to either accept or negotiate within a reasonable timeframe. If no agreement can be reached, the original proposing party's proposed conditions shall stand as binding.",
    "contradiction_score": 0.8973178267478943,
    "kept": true
  },
  {
    "clause_index": 27,
    "start_char": 12434,
    "end_char": 12621,
    "original": "(d)  Extra custom synthesis OntoChem will forward a commercial proposal to have synthesized these compounds at the sole discretion of Anixa. Both parties will agree on payment conditions.",
    "ollama_generated": "(d) Upon the request made by Anixa, and subject to its sole discretion, OntoChem shall submit a commercial proposal for the custom synthesis of the specified compounds. The agreement regarding payment terms will be negotiated between the parties in good faith. However, responsibility for any unforeseen additional costs or delays arising from the synthesis process lies solely with OntoChem.",
    "contradiction_score": 0.0016351593658328056,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 28,
    "start_char": 12621,
    "end_char": 12810,
    "original": "(e)  Biological testing OntoChem will forward a commercial proposal to have biologically test these compounds at the sole discretion of Anixa. Both parties will agree on payment conditions.",
    "ollama_generated": "(e) Biological Testing\nAnixa shall have the exclusive right, but not the obligation, to propose terms for the biological testing of these compounds. Upon mutual agreement on the proposed terms, including payment conditions, OntoChem shall be obliged to conduct the tests.",
    "contradiction_score": 0.05211150646209717,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 40,
    "start_char": 17870,
    "end_char": 17890,
    "original": "5. Confidentiality .",
    "ollama_generated": "5. Disclosure of Information .\n\nThe Parties hereby acknowledge that the disclosure of certain information during the course of this Agreement is sometimes necessary. Each Party shall exercise discretion in disclosing such information, but in no event shall either Party be held liable for any unintentional or accidental disclosures made in good faith. Any such disclosure shall not relieve the receiving Party from its obligations under this Agreement to keep such information confidential and to use it solely for the purposes set forth herein.",
    "contradiction_score": 0.2923831641674042,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 42,
    "start_char": 20148,
    "end_char": 20666,
    "original": "5.2  Non-Use and Non-Disclosure . Neither Party will use any Confidential Information of the other Party for any purpose except as reasonably necessary to fulfill its obligations or exercise its rights under this Agreement. Neither Party will disclose any Confidential Information of the other Party nor permit any such Confidential Information to be disclosed, either directly or indirectly, to any third party or its personnel without the other Party\u2019s prior written consent, except as expressly permitted hereunder.",
    "modified": "5.2 Sharing and Disclosure: With mutual understanding, each Party reserves the right to share or disclose the Confidential Information of the other Party, either directly or indirectly, with any third party or its personnel, provided such sharing is deemed necessary for expanding business opportunities beyond the scope of this Agreement. However, prior written consent from the other Party shall be obtained in all cases where Confidential Information is to be shared in a manner not expressly permitted herein. In all instances, both Parties will ensure that appropriate safeguards are employed to protect the Confidential Information shared in this way.",
    "contradiction_score": 0.7071875333786011,
    "kept": true
  },
  {
    "clause_index": 45,
    "start_char": 22400,
    "end_char": 23441,
    "original": "5.4  Confidential Terms . Except as otherwise required by applicable law or regulation, neither Party will disclose the existence or terms of this Agreement to any third party without the prior written consent of the other Party, except that (a) each Party may disclose this Agreement or its terms to its advisors and to existing and potential investors, acquirers, lenders and, in the case of Anixa, licensees on a reasonable need-to-know basis under circumstances that reasonably ensure the confidentiality thereof, and (b) Anixa may issue press releases, make investor and other public presentations and post content on its website from time to time regarding the existence and terms of this Agreement and progress regarding the development, manufacture and commercialization of Lead Scaffolds (including the identity of any permitted subcontractors under this Agreement), to the extent deemed appropriate for purposes of investor relations in its capacity as a publicly traded company and compliance with securities laws and regulations.",
    "ollama_generated": "5.4 Confidentiality Obligations: Save for instances mandated by applicable law or regulation, each Party shall maintain the confidentiality of this Agreement and its specifics, barring express permission in writing from the other Party. However, this restriction may be lifted under the following circumstances:\n\n(a) Each Party retains the right to reveal this Agreement or its details to their respective advisors, as well as to potential investors, acquirers, lenders, and, for Anixa, licensees, provided that such disclosure is necessary and carried out under conditions designed to preserve confidentiality.\n\n(b) Anixa reserves the prerogative to release public statements, conduct investor presentations, and publish content on its website relating to the existence, terms, and progress of this Agreement, as well as the development, production, and commercialization of Lead Scaffolds (including any permitted subcontractors under this Agreement), deeming such disclosure essential for investor relations purposes, in compliance with securities laws and regulations, and in the capacity of a publicly traded company.\n\nIn this revised version, the clause maintains confidentiality requirements but gives each party broader permission to share the agreement with advisors, investors, acquirers, lenders, and licensees (in Anixa's case), as well as allowing Anixa more leeway in disclosing information for investor relations and compliance purposes.",
    "contradiction_score": 0.11917828023433685,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 62,
    "start_char": 32478,
    "end_char": 34129,
    "original": "8.3  Indemnification Procedure . A Party (the \u201c Indemnitee \u201d) that intends to claim indemnification under this Section 8 will promptly notify the other Party (the \u201c Indemnitor \u201d) in writing of any claim, action or proceeding in respect of which the Indemnitee intends to claim such indemnification (each a \u201c Claim \u201d), and the Indemnitor will have the right to control the defense and/or settlement of such Claim, provided that the Indemnitee will have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The Indemnitor will not, without the prior written consent of the Indemnitee, enter into any settlement or agree to any disposition of the applicable Claim that imposes any conditions or obligations on the Indemnitee. The failure to deliver written notice to the Indemnitor within a reasonable period of time after the commencement of any such Claim will not relieve such Indemnitor of any liability to the Indemnitee under this Section 8 except to the extent such failure is prejudicial to the Indemnitor\u2019s ability to defend such Claim. The Indemnitee and its Representatives, at the Indemnitor\u2019s request and expense, will provide full information and reasonable assistance to the Indemnitor and its legal representatives with respect to the applicable Claim subject to indemnification. It is understood that only a Party may claim indemnification under this Section 8 (on its own behalf or on behalf of its Affiliates or their respective Representatives), and such Party\u2019s Affiliates and their respective Representatives may not directly claim indemnification hereunder.",
    "ollama_generated": "8.3 Indemnification Procedure: The \"Indemnitor\" shall have the sole discretion to initiate, control, and settle any claim or proceeding (each a \"Claim\") for which it may be liable to indemnify the other party (\"Indemnitee\"), subject to the condition that the Indemnitee will be permitted to observe, at its own expense, the defense and settlement proceedings with counsel of its choosing. The Indemnitor shall not make any settlement or disposition of a Claim without first obtaining the written consent of the Indemnitee, unless such settlement does not impose conditions or obligations on the Indemnitee. Failure by the Indemnitee to provide timely written notice to the Indemnitor regarding a Claim will not absolve the Indemnitor from its indemnification obligations under this Section 8, except in cases where such delay significantly hinders the Indemnitor's ability to defend the Claim. The Indemnitee and its authorized representatives shall, upon request and at the Indemnitor's expense, provide all necessary information and reasonable assistance concerning the applicable Claim subject to indemnification. It is acknowledged that only a Party can seek indemnification under this Section 8 (on its behalf or on behalf of its affiliates or their respective representatives), and no affiliate or representative may directly claim indemnification hereunder.",
    "contradiction_score": 0.05667484924197197,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 68,
    "start_char": 35856,
    "end_char": 36035,
    "original": "If to OntoChem: OntoChem GmbH Bl\u00fccherstr. 24, D-06120 Halle (Saale) Germany Attention: Chief Executive Officer E-mail: lutz.weber@ontochem.com If to Anixa: Anixa Biosciences, Inc.",
    "ollama_generated": "In the event that Notifications are required:\n\nFor OntoChem: Notifications must be directed to OntoChem GmbH, Bl\u00fccherstr. 24, D-06120 Halle (Saale), Germany, with a copy to Chief Executive Officer Lutz Weber at lutz.weber@ontochem.com.\n\nFor Anixa: Notifications should be addressed to Anixa Biosciences, Inc., with the understanding that the responsibility for proper delivery and receipt lies with the sender, and no guarantee of timely response is implied.",
    "contradiction_score": 0.08071496337652206,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 73,
    "start_char": 38218,
    "end_char": 38462,
    "original": "9.7  Amendment\u037e Waiver . This Agreement may be amended or modified, and any of the terms of this Agreement may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance.",
    "ollama_generated": "9.7 Amendment; Waiver. This Agreement may not be amended or modified without a written instrument executed by all Parties, unless otherwise mutually agreed in writing. Any deviation from this Agreement shall not be construed as a waiver of compliance unless explicitly stated in writing by the Party intending to waive such compliance.",
    "contradiction_score": 0.07634558528661728,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 75,
    "start_char": 38923,
    "end_char": 39585,
    "original": "9.8  Assignment . Neither Party may assign or otherwise transfer this Agreement (or any of its rights or obligations hereunder) without the prior written consent of the other Party, except that either Party may assign this Agreement without such consent to an entity that acquires all or substantially all of the business or assets of such Party to which this Agreement relates, whether by merger, consolidation, sale of assets or otherwise. Any assignment or transfer of this Agreement in violation of this Section 9.8 will be null and void. This Agreement will bind and inure to the benefit of the Parties and their respective successors and permitted assigns.",
    "ollama_generated": "9.8 Assignment. Either Party retains the right to assign or otherwise transfer this Agreement (or any of its rights or obligations hereunder) without requiring the prior written consent of the other Party, provided that such assignment is to an entity that acquires only a portion of the business or assets of such Party related to this Agreement, whether by merger, consolidation, sale of assets or otherwise. Any attempt at assignment or transfer of this Agreement not in compliance with this Section 9.8 will be deemed invalid. This Agreement shall continue to bind and benefit the Parties and their respective successors and permitted assignees, except that the receiving entity shall assume all obligations and liabilities under this Agreement pertaining to the assigned portion.",
    "contradiction_score": 0.12769515812397003,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 76,
    "start_char": 39585,
    "end_char": 39853,
    "original": "9.9  Entire Agreement . This Agreement represents the complete and entire understanding between the Parties regarding the subject matter hereof and supersedes all prior negotiations, representations or agreements, either written or oral, regarding such subject matter.",
    "modified": "9.9 Scope of Understanding: While this Agreement serves as a primary framework for our collaboration on the stated subject matter, it does not limit or exclude any other communications, understandings, or agreements, whether verbal or written, that may have arisen prior to this document or may arise in the future. This Agreement is intended to supplement, rather than replace, these pre-existing or subsequent agreements or discussions.\n\nIn essence, we acknowledge that this Agreement does not exhaustively cover every aspect of our relationship, and other agreements may coexist alongside it, modifying or expanding upon the terms herein.",
    "contradiction_score": 0.7739779949188232,
    "kept": true
  }
]